<DOC>
	<DOCNO>NCT01919723</DOCNO>
	<brief_summary>This purpose study measure platelet response ticagrelor eptifibatide bolus-only compare ticagrelor eptifibatide bolus plus 2-hour infusion administrate cardiac catheterization patient undergo non-emergent percutaneous coronary intervention .</brief_summary>
	<brief_title>Ticagrelor Eptifibatide Bolus-Only Versus Ticagrelor Eptifibatide Bolus Plus Abbreviated Infusion</brief_title>
	<detailed_description>In study , 70 patient Acute Coronary Syndrome undergo non-emergent percutaneous coronary intervention ( PCI ) randomize ticagrelor load dose eptifibatide bolus-only versus ticagrelor load dose eptifibatide bolus plus 2 hour infusion administrate cardiac catheterization , PCI . Platelet function test perform baseline follow-up .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>For inclusion study subject fulfill follow criterion : Provision inform consent prior study specific procedure Males female age 19 year old Congruent PLATO trial , least two follow three criterion meet : STsegment change electrocardiography , indicate ischemia ; ( In electrocardiography , ST segment connects QRS complex T wave duration 0.080 0.120 sec ( 80 120 m ) . positive test biomarker , indicate myocardial necrosis ; one several risk factor ; age &gt; 60 year previous myocardial infarction CoronaryArtery Bypass Grafting [ CABG ] ; coronary artery disease stenosis ≥50 % least two vessel ; previous ischemic stroke , transient ischemic attack , carotid stenosis least 50 % , cerebral revascularization ; diabetes mellitus ; peripheral arterial disease ; chronic renal dysfunction , define creatinine clearance &lt; 60 ml per minute per 1.73 m2 body surface area ) . patient symptoms unstable angina last ≥10 min either elevate troponin I level newly develop STsegment depression 1 mm transient STsegment elevation 1 mm also include . Subjects enter study follow exclusion criterion fulfil : Patients active pathological bleeding history intracranial bleeding ; patient plan urgent coronary artery bypass graft surgery ; severe hepatic impairment ; concomitant therapy strong cytochrome P450 3A inhibitor , 3A subfamily cytochrome P450 superfamily gene ; surgery &lt; 4 week ; use thienopyridine ( within previous two week ) ; upstream use Glycoprotein ( GP ) IIb/IIIa inhibitor ; bleed diathesis major bleed episode within 2 week ; need oral anticoagulation therapy ; thrombocytopenia ; presence thrombus coronary artery ; incessant chest pain hemodynamic instability ; patient glomerular filtration rate ( GFR ) &lt; 30 mL/min hemodialysis . maintenance dose aspirin 100mg history allergy Ticagrelor patient increase risk bradycardic event ( e.g. , patient sick sinus syndrome , 2nd 3rd degree Atrioventricular block ( AV block ) , bradycardic relate syncope protect pacemaker woman pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PCI</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Eptifibatide</keyword>
</DOC>